Atossa Therapeutics (ATOS) Issues New U.S. Patent
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St set to open higher as chip stocks extend recovery; earnings in focus
- Oil prices rise nearly 2% on fresh attacks by US and Iran
- Chip stocks extend global rebound following last week's rout
- Citi's Chew says U.S. stock positioning unwind may not be over
- Adobe, Salesforce and Intuit fall as Morgan Stanley begins cautious coverage
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio
April 22, 2025 8:45 AM EDTSEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,275,684) directed to enteric oral formulations comprising (Z)-endoxifen as well as methods of treating subjects with those oral formulations.
This newly granted patent further fortifies Atossas intellectual property portfolio surrounding its proprietary (Z)-endoxifen formulations, encompassing novel compositions and methods related to (Z)-endoxifen, a potent Selective... More
